This launch follows CE mark approval in Europe.

The soft, thin and flexible collagen pad consists of a specifically-formulated porous collagen matrix, coated on one side with a thin protein bonding layer (known as NHS-PEG).

This gives the pad a dual-method mechanism of action, in which two components interact to achieve hemostasis by sealing off the bleeding surface and initiating the body’s own clotting mechanisms.

Hemostatic performance, biocompatibility, and safety profile of HEMOPATCH has been proved in significant preclinical testing.

HEMOPATCH allows surgeons control during application for gaining hemostasis and firm adherence of the hemostatic pad to the bleeding tissue surface.

Baxte BioSurgery business research and development vice president Russell Holscher noted HEMOPATCH is a significant innovation in the field of surgical hemostasis and is a valuable enhancement to the portfolio of biosurgical products offered by the company.

”Importantly, the robust development process, including evaluation of more than 400 prototypes with feedback from more than 200 surgeons, exemplifies the company’s commitment to customer-centric innovation.

”This hemostat will offer surgeons a valuable new tool. We plan to support the registration and launch of HEMOPATCH in additional countries in the coming years,” Holscher added

HEMOPATCH demonstrated fast and effective hemostasis in preclinical tests, reaching 97.5% success by fully controlling bleeding at two minutes.